Exit Options for John Hancock Bond and Corporate Finance Group: Hanover Communications In... - 28 Strategic Investors

View x

Synedgen Receives $2.6 Million in Private Financing For Wound Care Portfolio

Synedgen, a biotechnology company using glycochemistry to develop drugs that enhance and mimic the innate immune system, announced that it has received $2.6 million in private financing to fund the commercialization of Catasyn™ Advanced Technology Wound Hydrogel and SynePure™ Wound Cleanser, two U. S. Food and Drug Administration 510(k)-cleared products that form part of Synedgen’s Wound Care portfolio. The development of Catasyn and SynePure, which address complex wounds, has been supported respectively by U.S. Army and Defense Advanced Research Projects Agency grants. Clinical trials are planned for both products in anticipation of increasing their technological readiness level for broad DoD adoption.